Head-to-head
SS-31 vs MOTS-c
A field-by-field comparison of SS-31 and MOTS-c drawn from the PeptideIndex database: mechanism, evidence grade, half-life, administration route, reported dosing, side effects, storage and legal status. They belong to different categories — longevity and metabolic — so this page focuses on what each one actually does rather than which is "better".
SS-31 vs MOTS-c: what's the main difference?
SS-31 and MOTS-c are both discussed in mitochondrial and healthy-ageing research, but they are biologically different compounds that do not share one mechanism. SS-31 (elamipretide) is a synthetic peptide that targets the inner mitochondrial membrane, and it has a more established clinical-development history in humans, including a phase 3 trial in primary mitochondrial myopathy that did not meet its primary endpoints. MOTS-c is a naturally occurring mitochondrial-derived peptide with strong mechanistic and preclinical interest, but far more limited direct therapeutic evidence in humans. Neither has been shown to extend human lifespan, and neither is approved as a medicine for general or anti-ageing use.
SS-31 vs MOTS-c: evidence summary
| Feature | SS-31 | MOTS-c |
|---|---|---|
| Also known as | Elamipretide (MTP-131) | Mitochondrial open reading frame of the 12S rRNA-c |
| Type | Synthetic mitochondria-targeting tetrapeptide | Naturally occurring mitochondrial-derived peptide (16 amino acids) |
| Main research focus | Mitochondrial disease and other disease-specific clinical settings | Metabolic regulation, exercise-related biology, ageing biology |
| Proposed mechanism | Binds cardiolipin in the inner mitochondrial membrane | Mitochondrial-to-nuclear signalling; folate/AMPK metabolic pathways |
| Human evidence | Randomised trials in disease populations | Mostly observational/physiology (endogenous levels); interventions largely in animals |
| Clinical-development status | Phase 3 completed in primary mitochondrial myopathy (primary endpoints not met); investigational | No substantial clinical-trial programme identified |
| Longevity evidence | No human lifespan evidence | No human lifespan evidence |
| Main limitation | Mixed trial results; data come from disease populations, not ageing | Therapeutic benefit in humans not established |
| PeptideIndex evidence grade | Moderate | Emerging |
What is SS-31?
SS-31, also known as elamipretide, is a mitochondria-targeting peptide. Research has focused on mitochondrial function and on disease-specific clinical settings such as primary mitochondrial myopathy, and it has progressed into human clinical development. It remains investigational. See the SS-31 profile.
What is MOTS-c?
MOTS-c is a mitochondrial-derived peptide encoded within the mitochondrial genome. Research has focused on metabolic signalling, exercise-related biology and mitochondrial function. Much of the strongest evidence remains mechanistic or preclinical, and human studies measuring natural MOTS-c levels do not by themselves establish a therapeutic benefit. See the MOTS-c profile.
How do SS-31 and MOTS-c work differently?
SS-31 / elamipretide
Mechanistic research describes SS-31 concentrating in the inner mitochondrial membrane and binding cardiolipin, a lipid involved in cristae structure and electron-transport function. This is mechanistic evidence; it does not by itself show clinical benefit.
MOTS-c
MOTS-c is described as a mitochondrial-derived signal that can move to the nucleus under metabolic stress and influence metabolic-response pathways, including folate/AMPK-related signalling, largely in cell and animal studies.
Neither peptide has one universally established mechanism that explains every effect attributed to it online.
Which has stronger human evidence?
SS-31. Under the PeptideIndex framework SS-31 is graded Moderate and MOTS-c Emerging. SS-31/elamipretide has a more developed human clinical-trial programme, although its phase 3 trial in primary mitochondrial myopathy did not meet its primary endpoints. MOTS-c has human biology research — mainly measurements of natural levels and associations with age, exercise or metabolic status — which is not the same as therapeutic clinical-trial evidence. See the Peptide Evidence Index for how grades are assigned.
- Human clinical outcomes → strongest relevance
- Human physiological / biomarker evidence → useful but indirect
- Animal studies → hypothesis-generating
- Mechanistic / cell research → biological plausibility
Which is better supported for longevity?
Neither can be called the better longevity peptide. Both have a mitochondrial rationale. SS-31 has disease-specific human trial evidence, not ageing outcomes. MOTS-c has metabolic evidence that is mostly preclinical. Direct human lifespan-extension evidence is absent for both.
What about exercise and metabolic research?
MOTS-c has attracted interest in metabolic regulation, exercise-related biology and mitochondrial signalling. Findings on improved metabolism or physical capacity come mainly from mice; human research largely shows how natural MOTS-c levels relate to exercise or age. Therapeutic or performance outcomes in humans have not been demonstrated.
Which has gone further in human clinical trials?
SS-31. Elamipretide has been through phase 2 and phase 3 trials in primary mitochondrial myopathy and has been studied in other disease-specific settings; it remains investigational. No substantial MOTS-c clinical-trial programme has been identified.
SS-31 vs MOTS-c: claims vs evidence
| Claim | What the evidence supports |
|---|---|
| SS-31 improves mitochondrial function | Supported mechanistically and studied clinically in specific conditions, with mixed results on primary endpoints |
| MOTS-c improves metabolism | Strong preclinical rationale; direct human intervention evidence is limited |
| SS-31 extends lifespan | Not demonstrated in humans |
| MOTS-c extends lifespan | Not demonstrated in humans |
| Both are proven anti-ageing peptides | Not supported |
Sources
- Karaa et al. — Elamipretide in primary mitochondrial myopathy: the MMPOWER-3 randomised clinical trial, Neurology (2023) — Human phase 3 trial; primary endpoints not met
- Lee et al. — The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis, Cell Metabolism (2015) — Primary mechanistic and mouse research; not human efficacy evidence
- Reynolds et al. — MOTS-c and age-dependent physical decline, Nature Communications (2021) — Treatment tested in mice; human component measured endogenous levels
More context: Longevity peptides guide · Editorial methodology
SS-31 vs MOTS-c at a glance
| Attribute | SS-31 | MOTS-c |
|---|---|---|
| Category | Longevity | Metabolic |
| Evidence grade | Moderate | Emerging |
| Also known as | Elamipretide, MTP-131 | Mitochondrial open reading frame of the 12S rRNA-c, MT-RNR1-encoded peptide |
| Chain | Tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2) | 16 amino acid mitochondrial-derived peptide |
| Mechanism | Concentrates in the inner mitochondrial membrane where it binds cardiolipin, stabilising cristae architecture, improving electron-transport efficiency and reducing reactive oxygen species leakage. | Encoded by mitochondrial 12S rRNA, MOTS-c translocates to the nucleus and activates the folate/AMPK axis. This improves cellular glucose uptake, increases fatty-acid oxidation and promotes metabolic flexibility under nutrient stress. |
| Reported benefits | Improved mitochondrial ATP output · Reduced oxidative stress markers · Fatigue improvement in mitochondrial disease trials | Improved insulin sensitivity and glucose disposal in rodent models · Enhanced fat oxidation and reduced fat accumulation · Exercise-mimetic effects on metabolism and physical capacity · Potential protection against diet-induced metabolic dysfunction |
| Reported side effects | Injection-site reactions are common and can be significant · Headache · Dizziness | Limited human safety data · Injection-site irritation · Possible hypoglycaemia in susceptible individuals |
| Half-life | Roughly 2 hours | Estimated minutes to a few hours |
| Legal status | Investigational drug, not approved for general use. | Research chemical; not approved as a drug. |
Key differences between SS-31 and MOTS-c
Different categories, different goals
SS-31 is indexed under longevity, while MOTS-c sits under metabolic. They are not substitutes for one another: SS-31 is described as "A mitochondria-targeting peptide in late-stage clinical trials for primary mitochondrial myopathy and rare eye disease." and MOTS-c as "A mitochondrial-encoded peptide that acts as a metabolic regulator, studied for insulin sensitivity, fat oxidation and exercise-mimetic effects."
Mechanism of action
SS-31: Concentrates in the inner mitochondrial membrane where it binds cardiolipin, stabilising cristae architecture, improving electron-transport efficiency and reducing reactive oxygen species leakage. MOTS-c: Encoded by mitochondrial 12S rRNA, MOTS-c translocates to the nucleus and activates the folate/AMPK axis. This improves cellular glucose uptake, increases fatty-acid oxidation and promotes metabolic flexibility under nutrient stress.
Evidence quality is not equal
SS-31 carries a Moderate evidence grade and MOTS-c a Emerging grade on this index. The grade describes the quality of published human data, not how well a compound works — SS-31 has the better-documented record of the two, and claims made about MOTS-c rest on thinner human evidence.
Half-life and dosing frequency
SS-31 is listed at roughly 2 hours; MOTS-c at estimated minutes to a few hours. That difference is what drives the reported schedules: Trial dosing around 40 mg daily; community protocols use less versus Commonly cited at 5–10 mg daily, often for 4–12 week cycles
Route of administration
SS-31 is administered by daily subcutaneous injection. MOTS-c is administered by subcutaneous injection; oral capsules are marketed but less validated.
Legal and regulatory status differs
SS-31: Investigational drug, not approved for general use. MOTS-c: Research chemical; not approved as a drug. This is usually the most practical difference between two compounds, because it determines whether a supply chain is labelled and regulated at all.
Handling and storage
SS-31 is stored refrigerate; protect from light. MOTS-c is stored lyophilised powder refrigerated; reconstituted vials 2–8 °c and used within ~30 days.
What SS-31 and MOTS-c have in common
On the attributes tracked in this database — category, evidence grade, mechanism, half-life, administration, dosing overview, storage and legal status — SS-31 and MOTS-c share no identical values. They are compared here because they come up together in the same searches, not because they overlap.
Each compound in brief
SS-31
Longevity · Moderate evidence
A mitochondria-targeting peptide in late-stage clinical trials for primary mitochondrial myopathy and rare eye disease.
Considerations: Human evidence exists but for disease populations, not healthy performance · Costly and typically injected daily · Trial results have been mixed on primary endpoints
MOTS-c
Metabolic · Emerging evidence
A mitochondrial-encoded peptide that acts as a metabolic regulator, studied for insulin sensitivity, fat oxidation and exercise-mimetic effects.
Considerations: Most evidence is preclinical; human trials are small and early-phase · Short half-life may require daily or twice-daily dosing · Bioavailability of oral forms is uncertain compared with injection
Related comparisons and reading
Every figure on this page is reproduced from the compound profiles in this database and reflects published literature and commonly reported protocols. It is educational information, not medical advice, and not a recommendation to use either compound. See the medical disclaimer.